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Abstract. In April 2004, 137 children 6–59 months of age with uncomplicated Plasmodium falciparum (Pf) malaria
(Caala, Central Angola) were randomized to receive either artemether-lumefantrine (Coartem) or artesunate + amo-
diaquine (ASAQ). After 28 days of follow-up, there were 2/61 (3.2%) recurrent parasitemias in the Coartem group and
4/64 (6.2%) in the ASAQ group (P  0.72), all classified as re-infections after PCR genotyping (cure rate  100%
[95%CI: 94–100] in both groups). Only one patient (ASAQ group) had gametocytes on day 28 versus five (Coartem) and
three (ASAQ) at baseline. Compared with baseline, anemia was significantly improved after 28 days of follow-up in both
groups (Coartem: from 54.1% to 13.4%; ASAQ: from 53.1% to 15.9%). Our findings are in favor of a high efficacy of
both combinations in Caala. Now that Coartem has been chosen as the new first-line anti-malarial, the challenge is to
insure that this drug is available and adequately used.
Angola reports 1.5 million clinical cases of malaria each
year.
1 After studies conducted in 2002 in several sites docu-
mented high failure rates of first- (chloroquine [CQ]) and
second-line (sulfadoxine-pyrimethamine [SP]) drugs,
2 the
country decided to shift to artemisinin-based combination
(ACT), namely artemether-lumefantrine (Coartem; Novartis
Pharma, Basel, Switzerland).
3 We report the results of an
ACT in vivo efficacy study conducted 2 years later in Caala
where high (CQ, 83.5%), rather high (SP, 25.3%), and rela-
tively low (amodiaquine [AQ], 17.3%) failure rates of mono-
therapies had been recorded in 2002.
2 We measured the ef-
ficacy of artemether + lumefantrine (Coartem), the newly
introduced first-line drug, and that of an alternative, namely
amodiaquine + artesunate (ASAQ). The study was approved
by the Ministry of Health of Angola.
The study was conducted in Caala town located in a meso-
endemic area of Huambo province (central Angola) previ-
ously described.
2 The design was the classic World Health
Organization (WHO) protocol for assessing the in vivo effi-
cacy of antimalarials in areas of high transmission.
4 It fol-
lowed the latest recommendations and outcome definitions.
4
In brief, children 6–59 months of age with confirmed clinical
pf malaria and responding to well-defined inclusion and ex-
clusion criteria
4 were recruited at the Caala health center,
after written, informed consent was obtained from caregivers.
Patients were randomized to receive either ASAQ (4 mg/kg/
day; Arsumax; Sanofi, Paris, France and 10 mg base/kg/day;
Camoquine; Park Davis, Dakar, Senegal) or artemether +
lumefantrine (Coartem, 20 mg arthemeter + 120 mg lumefan-
trine; Novartis Pharma, Dhaka, Bangladesh) for 3 days. The
dosage of Coartem (twice daily for 3 days) depended on body
weight and followed manufacturer’s instructions. All doses
were directly observed at the health center except for the
evening doses of Coartem, which were given at home under
the supervision of a health worker.
On day 0, hemoglobin (Lovibond; Assistant Co., Sondheim
Rhon, Germany) and presence of gametocytes were re-
corded, and a capillary blood sample was collected (Whatman
no. 3) for possible genotypic analysis to distinguish recrudes-
cence from re-infections. After treatment (days 0, 1, and 2),
children were re-assessed clinically and parasitologically on
days 3, 7, 14, 21, and 28. Hemoglobin and presence of game-
tocytes were re-measured on day 28, and a second blood
sample was collected for genotypic analysis in case of recur-
rence. Rescue therapy with quinine was administered on
treatment failure. Children were withdrawn from the study
during follow-up in case of 1) vomiting any study dose twice,
2) serious allergic reaction to study drug, 3) onset of a serious
febrile illness, 4) intake of any anti-malarial, 5) mixed para-
sitemia, and 6) withdraw of consent. Children who skipped
any dose or did not finish the 28-day follow-up were consid-
ered lost to follow-up.
Examination for malarial parasites followed WHO recom-
mendations,
5 with slides being checked at the laboratory by a
senior supervisor who made the final decision concerning pa-
tient classification. In addition, as a quality control procedure,
100 slides (50 positive and 50 negative) were checked in an
independent laboratory (Mbarara, Uganda) by a trained
laboratory technician masked to the original results (results
showed that 4% were discordant, i.e., there was a difference
in parasite density > 50% between the two readings, but none
of these differences changed the classification of the patient).
Anemia was defined as hemoglobin < 11 g/dL. The genotypic
analysis was performed at the Epicentre laboratory at
Mbarara University (Uganda) according to a published
method considering the three P. falciparum gene loci mero-
zoite surface protein-1 (msp-1), merozoite surface protein-2
(msp-2), and glutamate rich protein (GLURP).
6 Cases in
which pre- and post-treatment genotypes were identical were
considered as recrudescence, i.e., failures; cases in which pre-
and post-treatment genotypes were different were considered
as re-infections; mixed genotypes were classified as failures.
Data were entered in EpiData (The EpiData Association,
Odense, Denmark) and analyzed in Stata 8.2 (Stata, College
Station, TX).
Between April and July 2004, 742 children were screened;
137 were included and randomized in the Coartem (68) and
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143ASAQ (69) groups (Figure 1). Baseline characteristics were
similar across treatment groups (Table 1). Eleven patients
(8.0%) were excluded during follow-up, and 1 (0.7%) was lost
to follow-up, leaving 61 (Coartem) and 64 (ASAQ) patients
for analysis (Figure 1). After 28 days, there were 2/61 (3.2%)
recurrent parasitemias in the Coartem group and 4/64 (6.2%)
in the ASAQ group (P  0.72). These recurrences were all
classed as re-infections after polymerase chain reaction
(PCR) analysis (cure rate  100%; 95% CI, 94–100 in both
groups). Only one (1.5%) patient (in the ASAQ group) had
gametocytes on day 28 versus five (7.3%, Coartem) and three
(4.3%, ASAQ) at baseline. Compared with baseline, anemia
was significantly improved after 28 days of follow-up in both
groups (Coartem: from 54.1% [33/61] to 13.4% [8/60]; ASAQ:
from 53.1% [34/64] to 15.9% [10/63]); the patient missing in
each denominator on day 28 corresponds to recurrent para-
sitemias before day 28 (i.e., patients not attending day 28).
This in vivo study provides new data on the efficacy of two
artemisinin-based combinations in an area of Angola where
no information on ACT efficacy was available. It provides
new information on the performance of ASAQ and Coartem
(Angola’s new first-line anti-malarial regimen) based on a
PCR-adjusted 28-day follow-up.
The main limitation of this study was its rather small
sample size, and we acknowledge that this was a weakness in
this trial. Indeed, because the efficacy of both drugs was high,
a study enrolling few patients in each arm was highly unlikely
to find any difference, even if one existed. However, our main
objective was not to compare one regimen against the other,
but rather to measure the individual efficacy of each treat-
ment. In this sense, we are confident that the design allowed
us to draw reliable conclusions regarding the efficacy of both
regimens. A second limitation is that the follow-up was rather
short, and therefore could have missed late recrudescent in-
fections appearing after day 28. However, extending the fol-
low-up to 42 days, which was recommended recently for the
assessment of Coartem,
7 was difficult in the context of a hu-
manitarian mission such as the one in Caala. Our estimates
are therefore likely to over-estimate, to some extent, the ef-
ficacy of each ACT. A final, although minor, point concerns
the examination of gametocytes, which was done through the
standard method recommended by the WHO to examine
asexual stages of the plasmodium. Reliable examining for ga-
metocytes requires at least 500 fields to be counted; therefore,
we may have under-estimated the presence of gametocytes.
Both combinations were highly efficacious, confirming re-
cent findings in Zanzibar.
8 In addition, both treatments re-
duced gametocyte carriage, which reflects transmissibility and
is an important consideration for malaria control programs.
Finally, the proportion of anemic children was significantly
reduced in both groups, when comparing baseline levels of
anemia to that at the end of follow-up. Anemia is aggravated
by parasite resistance,
9 which highlights the added benefit of
treating patients with a highly efficacious drug. For all these
reasons, Coartem and ASAQ are both valid alternatives for
treatment of P. falciparum malaria in this setting.
This is the first evaluation of the new malaria treatment
policy implemented in the country. Our results provide im-
portant baseline information on the efficacy of this new first-
line drug. Now that the decision to use Coartem has been
taken and funds have been made available to finance this
change,
10 the challenge is now to make the drug available and
to deploy the drug at the peripheral level to maximize its
effectiveness.
11 A recent study in Zambia showed that, even
where ACTs were freely available and clinic staff knew they
were being observed, only a low proportion of patients actu-
ally received them.
12 If we want the efficacy of this drug to
remain high in Angola, we need to ensure that it is adequately
used.
Received February 20, 2006. Accepted for publication March 1, 2006.
Financial support: This study was funded by Médecins sans Fron-
tières. The American Society of Tropical Medicine and Hygiene
(ASTMH) and the American Committee on Clinical Tropical Medi-
cine and Travelers’ Health (ACCTMTH) assisted with publication
expenses.
TABLE 1
Baseline (day 0) characterisitcs of included patients
Characteristic on inclusion Coartem (n  68) ASAQ (n  69) P value
Age (months) Median (IQR) 25 (18–37) 26 (16–42) 0.60
Sex ratio (M/F) 1.06 (35/33) 1.22 (38/31) 0.67
Malnutrition (MUAC < 125 mm) n (%) 10 (14.7) 4 (5.8) 0.08
Axillary temperature (°C) Median (IQR) 39 (38.3–39.8) 39 (38–40) 0.99
Hemoglobin (g/dL) Median (IQR) 10.7 (10.7–11.7) 10.7 (9.7–11.7) 0.39
Anemia (g/dL) 0.20
Moderate (5–7.9) n (%) 4 (5.9%) 10 (14.5%)
Mild (8–10.9) n (%) 34 (50%) 28 (40.6%)
Absence ( 11) n (%) 30 (44.1%) 31 (44.9%)
Presence of gametocytes n (%) 5 (7.3%) 3 (4.3%) 0.69
Parasitaemia (/L) Geometric mean (95% CI) 30,522 (25,354–36,742) 27,914 (22,584–34,503) 0.71
FIGURE 1. Details on study inclusions and follow-up.
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